Head-to-head · Cost-Efficiency Index
Hims & Hers vs Curex
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Hims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersCurex
People who want a low-cost first month, an oral option, and a verified pharmacy nationwide, and don't need a dose-by-dose price table before signing up.
Visit CurexThe verdict
Hims & Hers takes it, leading the Cost-Efficiency Index 83 to 81. Nationwide reach and a slick app at a mid-market semaglutide price — but an undisclosed tirzepatide price leaves part of the value equation blank. Curex still earns a B− — People who want a low-cost first month, an oral option, and a verified pharmacy nationwide, and don't need a dose-by-dose price table before signing up.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Hims & Hers.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Hims & Hers | Curex |
|---|---|---|
| Cost-Efficiency Index | 83/100 | 81/100 |
| Semaglutide / mo | $199/mo | $199/mo Starting (first month $49) |
| Tirzepatide / mo | Not disclosed | $199/mo Starting (first month $149) |
| Semaglutide / yr (modeled) | $2,388 | $2,388 |
| Tirzepatide / yr (modeled) | — | $2,388 |
| Coverage | All 50 states | All 50 states (California: oral tablet only, no injectable) |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #22 | #27 |
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
Curex
81/100Where the value is
- Discounted first month well below the ongoing rate — $49 for semaglutide, $149 for tirzepatide
- Nationwide enrollment (all 50 states) plus an oral/sublingual route as an alternative to injections
- 365-day money-back guarantee and a full refund if never prescribed
The tradeoffs
- The '$199/mo' figure is labeled 'Starting,' not flat — no dose-by-dose price table is published, so the real cost at a higher maintenance dose is unverified
- California residents cannot get the injectable route at all — oral tablets only, despite the 'all 50 states' enrollment claim
Regulatory note: the FDA issued a warning letter to Curex in September 2025. We still list and link to Curex; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.